A mga experimental KRAS-blocking drug shows minimal tumor-shrinking effects in patients with advanced colorectal cancer, raising new doubts whether the drug can be broadly effective against different types of solid tumors.
known as AMG 510, has generated considerable interest since the release of data showing the potential for shrinking tumors in lung cancer patients. But data presented on Saturday at this year's European Society for Medical Oncology meeting was more disappointing. Of 29 patients with advanced colorectal cancer treated with AMG 510 in Amgen's Phase 1 clinical trial, one patient showed partial shrinkage of the tumor. This is a response rate of 3%.